Human cytomegalovirus (CMV) represents the most common viral infection after hematopoietic stem cell transplant (HSCT), mainly occurring as reactivation from latency in seropositive patients, with a different prevalence based on the extent and timing of seroconversion in a specific population. Here, we retrospectively analyzed a cohort of patients who underwent HSCT at our Institution between 2013 and 2018, all of whom were prophylactically treated with CMV-IG (Megalotect Biotest®), to define the incidence and clinical outcomes of CMV reactivation and clinically significant infection. CMV infection occurred in 69% of our patient series, mainly resulting from reactivation, and CMV clinically significant infection (CS-CMVi) occurred in 48% of prophylactically treated patients. CMV infection and CS-CMVi impacted neither on relapse incidence nor on overall survival nor on relapse-free survival. Moreover, a very low incidence of CMV end-organ disease was documented. CMV-IG used alone as prophylactic therapy after HSCT does not effectively prevent CMV reactivation.

Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis / Gilioli, A.; Messerotti, A.; Bresciani, P.; Cuoghi, A.; Pioli, V.; Colasante, C.; Bettelli, F.; Giusti, D.; Forghieri, F.; Potenza, L.; Donatelli, F.; Giubbolini, R.; Galassi, L.; Marasca, R.; Banchelli, F.; D'Amico, R.; Pecorari, M.; Gennari, W.; Trenti, T.; Comoli, P.; Luppi, M.; Narni, F.. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 0146-6615. - 93:11(2021), pp. 6292-6300. [10.1002/jmv.26861]

Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis

Cuoghi A.;Potenza L.;Marasca R.;D'Amico R.;Luppi M.;Narni F.
2021

Abstract

Human cytomegalovirus (CMV) represents the most common viral infection after hematopoietic stem cell transplant (HSCT), mainly occurring as reactivation from latency in seropositive patients, with a different prevalence based on the extent and timing of seroconversion in a specific population. Here, we retrospectively analyzed a cohort of patients who underwent HSCT at our Institution between 2013 and 2018, all of whom were prophylactically treated with CMV-IG (Megalotect Biotest®), to define the incidence and clinical outcomes of CMV reactivation and clinically significant infection. CMV infection occurred in 69% of our patient series, mainly resulting from reactivation, and CMV clinically significant infection (CS-CMVi) occurred in 48% of prophylactically treated patients. CMV infection and CS-CMVi impacted neither on relapse incidence nor on overall survival nor on relapse-free survival. Moreover, a very low incidence of CMV end-organ disease was documented. CMV-IG used alone as prophylactic therapy after HSCT does not effectively prevent CMV reactivation.
2021
93
11
6292
6300
Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis / Gilioli, A.; Messerotti, A.; Bresciani, P.; Cuoghi, A.; Pioli, V.; Colasante, C.; Bettelli, F.; Giusti, D.; Forghieri, F.; Potenza, L.; Donatelli, F.; Giubbolini, R.; Galassi, L.; Marasca, R.; Banchelli, F.; D'Amico, R.; Pecorari, M.; Gennari, W.; Trenti, T.; Comoli, P.; Luppi, M.; Narni, F.. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 0146-6615. - 93:11(2021), pp. 6292-6300. [10.1002/jmv.26861]
Gilioli, A.; Messerotti, A.; Bresciani, P.; Cuoghi, A.; Pioli, V.; Colasante, C.; Bettelli, F.; Giusti, D.; Forghieri, F.; Potenza, L.; Donatelli, F.;...espandi
File in questo prodotto:
File Dimensione Formato  
Journal of Medical Virology - 2021 - Gilioli - Cytomegalovirus reactivation after hematopoietic stem cell transplant with.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.87 MB
Formato Adobe PDF
1.87 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1250053
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact